TherapeuticsMD swings to Q3 profit, license revenue climbs

Reuters

2025/11/13

TherapeuticsMD swings to Q3 profit, license revenue climbs

Overview

TherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last year
License revenue for Q3 rises due to changes in sales of licensed products
Company exploring strategic alternatives, no assurance of transaction outcome

Outlook

TherapeuticsMD is evaluating strategic alternatives, including mergers or asset sales
Company has not set a timetable for strategic evaluations

Result Drivers

LICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed products
OPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income from Cont Ops		$50,000
Q3 Operating Expenses		$1.65 mln

Press Release: ID:nBw8Hlscxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583583976"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583583976\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583583976?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583583976","market":"nz","top_or_hot":-1,"title":"TherapeuticsMD swings to Q3 profit, license revenue climbs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>TherapeuticsMD swings to Q3 profit, license revenue climbs</title></head><body><p><span>Overview</span></p><ul><li><p>TherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last year</p></li><li><p>License revenue for Q3 rises due to changes in sales of licensed products</p></li><li><p>Company exploring strategic alternatives, no assurance of transaction outcome</p></li></ul><p><span>Outlook</span></p><ul><li><p>TherapeuticsMD is evaluating strategic alternatives, including mergers or asset sales</p></li><li><p>Company has not set a timetable for strategic evaluations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed products</p></li><li><p>OPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income from Cont Ops</p></td><td></td><td><p>$50,000</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$1.65 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw8Hlscxa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TherapeuticsMD swings to Q3 profit, license revenue climbs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTherapeuticsMD swings to Q3 profit, license revenue climbs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>TherapeuticsMD swings to Q3 profit, license revenue climbs</title></head><body><p><span>Overview</span></p><ul><li><p>TherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last year</p></li><li><p>License revenue for Q3 rises due to changes in sales of licensed products</p></li><li><p>Company exploring strategic alternatives, no assurance of transaction outcome</p></li></ul><p><span>Outlook</span></p><ul><li><p>TherapeuticsMD is evaluating strategic alternatives, including mergers or asset sales</p></li><li><p>Company has not set a timetable for strategic evaluations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed products</p></li><li><p>OPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income from Cont Ops</p></td><td></td><td><p>$50,000</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$1.65 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw8Hlscxa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXMD","symbol_name":"TherapeuticsMD Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO13F:1","article_id":"2583583976","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583583976","pubTimestamp":1762982693,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TherapeuticsMD swings to Q3 profit, license revenue climbsOverviewTherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last yearLicense revenue for Q3 rises due t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXMD":"TherapeuticsMD Inc.","BK4007":"制药"},"translate_title":"TherapeuticsMD第三季度盈利，许可收入攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXMD":0.9},"content_text":"TherapeuticsMD swings to Q3 profit, license revenue climbsOverviewTherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last yearLicense revenue for Q3 rises due to changes in sales of licensed productsCompany exploring strategic alternatives, no assurance of transaction outcomeOutlookTherapeuticsMD is evaluating strategic alternatives, including mergers or asset salesCompany has not set a timetable for strategic evaluationsResult DriversLICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed productsOPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income from Cont Ops$50,000Q3 Operating Expenses$1.65 mlnPress Release: ID:nBw8HlscxaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}